Sermorelin vs tesamorelin: different compounds, different data
Same target receptor, two very different molecules — and two very different evidence bases.
TL;DR
- Sermorelin and tesamorelin both nudge the pituitary to release growth hormone, but they are not interchangeable.
- Tesamorelin (brand name Egrifta) is longer-acting and FDA-approved for one specific population; the compounded version is not FDA-approved. Sermorelin is shorter-acting and used differently.
- Choosing between them is a clinician decision — not a marketing one.
What it is
Sermorelin is a 29-amino-acid copy of growth hormone-releasing hormone (in plain English: GHRH, the natural signal the brain sends to the pituitary). Tesamorelin is a 44-amino-acid stabilized version of GHRH with a longer half-life (Walker, Hormone Research, 2000; Falutz et al., AIDS, 2010).
How it works
Imagine two doorbells wired to the same kitchen timer. Both press the timer the same way. One press fades quickly. The other lingers a few minutes longer. That is roughly the difference between sermorelin and tesamorelin: same receptor, different staying power. Both prompt the pituitary to release the body's own growth hormone in a natural pulse rather than override that pulse with direct injection.
Who asks about it
People usually ask this question when a clinician offers them a choice, or when they read about both compounds in the same blog post and want to know what is actually different. The short answer: study population, half-life, and FDA status.
What the research says
The clearest difference is in how each compound has been studied. Sermorelin literature is older — pediatric growth hormone deficiency diagnostics in the 1990s, smaller adult studies later. Tesamorelin has the larger modern trial base, almost all of it in HIV-associated lipodystrophy (in plain English: a body-fat redistribution condition), where the branded product Egrifta received FDA approval; the compounded version is not FDA-approved. Tesamorelin trials show consistent reductions in visceral fat and increases in IGF-1 (a downstream marker of growth hormone activity) in that population (Falutz et al., 2010).
What to know before considering it
Compounded sermorelin is widely available through 503A pharmacies. Compounded tesamorelin is also available but is more expensive and rarely matches the dosing studied in trials. Neither compound is appropriate for people with active cancer, certain pituitary conditions, or untreated retinopathy. Compounded versions of both are not FDA-approved.
The Halftime POV
These are not interchangeable. Tesamorelin has a narrow approved use and a stronger trial record. Sermorelin has a longer wellness-context history and a milder profile. Picking between them is a clinician conversation. Picking neither, after that conversation, is also a fair answer.
Related reading:
- Sermorelin side effects: what the literature reports
- Tesamorelin (Egrifta) explained: the GHRH analog primer
- The growth hormone axis explained
FAQ
Q: What is the difference between sermorelin and tesamorelin? A: Sermorelin is a 29-amino-acid copy of GHRH with a short half-life. Tesamorelin is a 44-amino-acid stabilized GHRH analog with a longer half-life. The branded tesamorelin product Egrifta has a specific FDA-approved use in HIV-associated lipodystrophy; the compounded version is not FDA-approved. They share a target but differ in pharmacology and FDA status.
Q: Is tesamorelin stronger than sermorelin? A: Tesamorelin is more stable in the bloodstream, which lets it raise IGF-1 (a downstream marker of growth hormone) more reliably in published trials. "Stronger" depends on the goal — diagnostic, longevity research, or visceral fat reduction in a specific population.
Q: Are either of them FDA-approved? A: Tesamorelin is FDA-approved (brand name Egrifta) for excess abdominal fat in HIV-associated lipodystrophy. Sermorelin had historical FDA approval for pediatric growth hormone diagnostic use. Compounded versions of either are not FDA-approved and are prepared by state-licensed 503A pharmacies.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Hormone Research, 2000.
- Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 2010.
Frequently asked questions
What is the difference between sermorelin and tesamorelin?
Sermorelin is a 29-amino-acid copy of GHRH with a short half-life. Tesamorelin is a 44-amino-acid stabilized GHRH analog with a longer half-life. The branded tesamorelin product Egrifta has a specific FDA-approved use in HIV-associated lipodystrophy; the compounded version is not FDA-approved. They share a target but differ in pharmacology and FDA status.
Is tesamorelin stronger than sermorelin?
Tesamorelin is more stable in the bloodstream, which lets it raise IGF-1 (a downstream marker of growth hormone) more reliably in published trials. 'Stronger' depends on the goal — diagnostic, longevity research, or visceral fat reduction in a specific population.
Are either of them FDA-approved?
Tesamorelin is FDA-approved (brand name Egrifta) for excess abdominal fat in HIV-associated lipodystrophy. Sermorelin had historical FDA approval for pediatric growth hormone diagnostic use. Compounded versions of either are not FDA-approved and are prepared by state-licensed 503A pharmacies.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.